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1Coronary artery disease is the leading cause of mortal-ity and morbidity in industrialized countries.1 Coronary 
stents reduce the risk of periprocedural complications and 
restenosis when compared with angioplasty alone and have 
revolutionized interventional cardiology; however, in-stent 
restenosis remains a major clinical obstacle.2 Drug-eluting 
stents (DES) have emerged as a highly promising approach to 
reduce in-stent restenosis. In fact, first-generation DES, such 
as sirolimus or paclitaxel-eluting stents, and second-genera-
tion DES, such as everolimus or zotarolimus-eluting stents, 
have substantially reduced angiographic and clinical restenosis 
across broad lesions and patient subsets. Next-generation 
DES include stents with bioresorbable polymers and biore-
sorbable stents. However, despite remarkable improvements 
in stent platform, polymer, and drug, the long-term results of 
DES usage have been blighted by the dual problems of in-
stent restenosis and late stent thrombosis. DES unselectively 
inhibit migration and proliferation of both vascular smooth 
muscle cells (VSMCs) and endothelial cells (ECs) and are 
associated with increased thrombocyte activation and aggre-
gation compared with bare-metal stents.3–5 In addition, immu-
nosuppressive drugs, such as paclitaxel, decrease numbers and 
© 2016 American Heart Association, Inc.
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Objective—Drug-eluting coronary stents reduce restenosis rate and late lumen loss compared with bare-metal stents; 
however, drug-eluting coronary stents may delay vascular healing and increase late stent thrombosis. The peroxisome 
proliferator–activated receptor-delta (PPARδ) exhibits actions that could favorably influence outcomes after drug-eluting 
coronary stents placement.
Approach and Results—Here, we report that PPARδ ligand–coated stents strongly reduce the development of neointima 
and luminal narrowing in a rabbit model of experimental atherosclerosis. Inhibition of inflammatory gene expression and 
vascular smooth muscle cell (VSMC) proliferation and migration, prevention of thrombocyte activation and aggregation, 
and proproliferative effects on endothelial cells were identified as key mechanisms for the prevention of restenosis. Using 
normal and PPARδ-depleted VSMCs, we show that the observed effects of PPARδ ligand GW0742 on VSMCs and 
thrombocytes are PPARδ receptor dependent. PPARδ ligand treatment induces expression of pyruvate dehydrogenase 
kinase isozyme 4 and downregulates the glucose transporter 1 in VSMCs, thus impairing the ability of VSMCs to provide 
the increased energy demands required for growth factor–stimulated proliferation and migration.
Conclusions—In contrast to commonly used drugs for stent coating, PPARδ ligands not only inhibit inflammatory 
response and proliferation of VSMCs but also prevent thrombocyte activation and support vessel re-endothelialization. 
Thus, pharmacological PPARδ activation could be a promising novel strategy to improve drug-eluting coronary stents 
outcomes.  (Arterioscler Thromb Vasc Biol. 2016;36:00-00. DOI: 10.1161/ATVBAHA.115.306962.)
Key Words: blood platelets ◼ coronary restenosis ◼ muscle, smooth, vascular ◼ peroxisome  
proliferator-activated receptors ◼ stents
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proliferative, migratory, adhesive, and tube formation capaci-
ties of endothelial progenitor cells, which play an important 
role in re-endothelialization. Delayed re-endothelialization 
and impaired endothelial function after DES have been sug-
gested as a cause of increased rates of stent thrombosis com-
pared with bare-metal stents.6
The response to percutaneous coronary intervention (PCI)–
induced vascular injury is characterized by the sequence of 
inflammation, granulation, extracellular matrix synthesis, and 
VSMC proliferation and migration. In this process, VSMCs 
switch from a quiescent, contractile to a synthetic phenotype 
that proliferates and migrates in response to chemotactic fac-
tors,7 leading to neointimal thickening and restenosis.8 PCI-
induced vascular injury causes release of growth factors, 
mainly platelet-derived growth factor (PDGF), which is pro-
duced by VSMCs, ECs, platelets, or macrophages and plays an 
important role in neointima formation.9 In addition, previous 
studies have shown that glycolysis is enhanced in response to 
PDGF and changes in cell metabolism are both a hallmark and 
requirement for PDGF-induced cell proliferation.10,11
The peroxisome proliferator–activated receptor-delta 
(PPARδ, also called PPARβ), together with the other 2 sib-
lings, PPARα and PPARγ, belongs to the nuclear receptor 
superfamily of ligand-activated transcription factors. These 
receptors form heterodimers with retinoid X receptors and 
bind to consensus response elements in the promoter region 
of their target genes. In the absence of ligand, PPARδ–
retinoid X receptor heterodimers recruit corepressors, silenc-
ing transcription by the so-called active repression. Ligand 
binding induces a conformational change in PPAR–retinoid 
X receptor complexes, releasing corepressors in exchange 
for coactivators, which results in increased gene expres-
sion.12 The naturally occurring ligands for PPARδ include 
polyunsaturated fatty acids, triglycerides, and prostacyclin. 
In addition, highly potent and selective synthetic PPARδ ago-
nists such as GW501516 or GW0742 have been developed. 
PPARδ has been associated with regulation of inflammation, 
cell differentiation, proliferation, and apoptosis.13 Moreover, 
PPARδ has beneficial effects on whole-body metabolism 
and improves several parameters of the metabolic syndrome 
in defined mouse models.14 Preclinical and phase I/II trials 
suggest that PPARδ agonists increase high-density lipo-
protein and decrease low-density lipoprotein cholesterol, 
reduce body fat and improve markers of inflammation in 
obese subjects.15,16 These findings prompted us to perform a 
proof-of-concept study to determine whether PPARδ ligands 
inhibit in-stent restenosis in a rabbit model of experimental 
atherosclerosis.
In the present study, we outline a promising role for 
PPARδ ligand–coated stents to address drawbacks of cur-
rently used DES. We demonstrate in vivo that PPARδ 
ligand–coated stents lead to a significant inhibition of strut-
associated neointima when compared with vehicle-coated 
stents. This effect is mediated by a differential effect on 
VSMC and EC proliferation and migration, an attenuation 
of vascular inflammation, and an inhibition of thrombocyte 
activation and aggregation.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
PPARδ Ligand–Coated Stents Inhibit In-Stent 
Restenosis in Rabbit Atheromatous Arteries
Forty-six methylester conjugated PPARδ ligand 
(GW0742-Me)– or vehicle (ethanol)–coated stents (21 
mm×3.5 mm; Translumina GmbH) were successfully 
implanted in the aorta of rabbits. A rabbit model of experi-
mental atherosclerosis was used as described in the Method 
section of this article. To achieve a suitable release kinetic, we 
modified the synthetic PPARδ ligand GW0742 and produced 
methylester of GW0742 (GW0742-Me). Pharmacological 
release kinetic was determined ex vivo and in vivo (Results 
and Figures II and II in the online-only Data Supplement). 
Animals were randomized to either high-dose GW0742-
Me–coated stents (445.4±61.2 μg), low-dose GW0742-
Me–coated stents (151.2±15.4 μg), or vehicle-coated stents 
(ethanol). Time points for euthanasia were 14 and 42 days 
after stent deployment (Figure III in the online-only Data 
Supplement). The rabbits appeared healthy with no signs of 
drug toxicity identified by weight loss, lethargy, or icterus. 
We collected blood samples for differential blood count, lipid 
profile, glucose, C-reactive protein, liver and kidney values 
at the time of aortic denudation, at the end of the atherogenic 
diet, before stent placement, and at day 14 and 42 after stent 
deployment. At all time points, analyzed laboratory values 
were not significantly different among the groups (Table I in 
the online-only Data Supplement).
PPARδ ligand–coated stents lead to a significant inhibi-
tion of strut-associated neointimal area (29.57% inhibition 
with high-dose and 46.65% with low-dose–coated stents; 
P<0.05) compared with vehicle (ethanol)–coated stents 
(Figure 1A and 1C). In addition, cellular proliferation was 
significantly reduced both in the neointimal area (65.36% 
inhibition with high-dose and 79.35% with low-dose–coated 
stents; P<0.05) and in the underlying plaque area (53.6% 
inhibition with high-dose and 74.17% with low-dose–coated 
stents; P<0.05; Figure 1B and 1C). Neointimal smooth 
muscle cell (41.94% inhibition with high-dose and 53.04% 
with low-dose–coated stents; P<0.05) and macrophage cell 
Nonstandard Abbreviations and Acronyms
AMPK adenosine 5′-monophosphate-activated protein kinase
DES drug-eluting stent
HUVEC human umbilical vein endothelial cells
IL-6 interleukin-6
MCP-1 monocyte chemoattractant protein-1
PCI percutaneous coronary intervention
PDGF platelet-derived growth factor
PPARδ peroxisome proliferator–activated receptor-delta
rVSMCs rat VSMCs
TNFα tumor necrosis factor-α
VCAM vascular adhesion molecule
VSMC vascular smooth muscle cell
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area (40.09% inhibition for high-dose and 71.39% with low-
dose–coated stents; P<0.05) were significantly decreased 
with PPARδ ligand–coated stents compared with the control 
group (Figure 1C). Morphometric analysis of stented rabbit 
aortas revealed no difference between the groups with respect 
to external elastic lamina area, stent area, and atherosclerotic 
plaque area (data not shown).
We next examined inflammatory gene expression in stented 
and unstented rabbit aortas. PPARδ ligand–coated stents sig-
nificantly attenuated monocyte chemoattractant protein-1 
(MCP-1; 41.66% inhibition with low dose; P<0.05) and inter-
leukin-6 (IL-6) mRNA expression (47.3% inhibition with low 
dose; P<0.05) at 42 days after stent placement (Figure 1D, left), 
whereas no effect on vascular cell adhesion molecule (VCAM) 
expression was observed (data not shown). In contrast, no dif-
ference in gene expression was observed in the arterial wall 
adjacent to the unstented segments (Figure 1D, right).
PPARδ Activation Inhibits VSMC 
Proliferation and Migration
VSMC proliferation and migration stimulated by PDGF play a 
crucial role in the progression of atherosclerosis and the devel-
opment of restenosis after coronary angioplasty.17,18 Previous 
reports suggest that different PPARδ ligands potentiate cell 
growth, whereas other studies suggest an attenuation of cell 
growth by PPARδ activation.19–22 To further analyze the effect 
of PPARδ activation on VSMC growth, the subtype-specific 
PPARδ agonist GW0742 was used in rat VSMCs (rVSMCs) 
vehicle coated stent G W -Me coated stent
(high dose)
G W -Me coated stent
(low dose)
x10
x1.25
A
B
S
S
S
N
A
M
vehicle coated stent G W -Me coated stent
(high dose)
G W -Me coated stent
(low dose)
x20
Figure 1. Stents coated with the peroxisome proliferator–activated receptor-delta (PPARδ) ligand GW0742-Me (GW-Me) inhibit in-stent 
restenosis and inflammatory gene expression in rabbit atheromatous arteries (n=8 per group for 14-d end point, n=10 per group for 42-d 
end point). Representative cross-sectional histology of the aorta 42 d after implantation of GW0742-Me (low dose and high dose)– or 
vehicle (EtOH)–coated stents. A, Photomicrographs of arterial sections stained with toluidine blue (×1.25 and ×10 magnification).  
B, Arterial sections immunohistochemically stained for KiS1 (×10 magnification). C, Histomorphometric analysis of rabbit (Continued )
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4  Arterioscler Thromb Vasc Biol  August 2016
resuming proliferation by PDGF-BB treatment after G0/G1-
phase synchronization. GW0742 treatment (Figure 2A, left) 
inhibited rVSMC proliferation in a dose-dependent manner 
(40.59% inhibition at 10 μmol/L GW0742; P<0.05). To further 
characterize the role of PPARδ in cell proliferation, VSMCs 
were isolated from the aorta of PPARδ+/+ and PPARδ−/− mice. 
Electron microscopy analysis of PPARδ−/− VSMCs revealed 
no morphological differences in size and structure of cell 
nuclei, mitochondria, endoplasmic reticulum, Golgi complex, 
and cell–cell contact compared with PPARδ+/+ VSMCs (data 
not shown). Incubation of PPARδ wild-type mouse VSMCs 
with GW0742 attenuated cell proliferation (32.13% inhibi-
tion at 3 μmol/L GW0742; P<0.05), whereas no effect was 
observed in PPARδ-depleted cells (Figure 2A, right).
To analyze individual rVSMC chemotaxis, vehicle-
treated (DMSO) or GW0742-treated cells were allowed 
to migrate in the presence of a PDGF-BB gradient. Cell 
tracks were recorded by time-lapse microscopy and the 
Euclidean distance (straight line between starting and end 
point), the total distance and the directionality of cell migra-
tion were determined. As shown in Figure 2B, GW0742 
treatment markedly reduced both the Euclidean distance 
(64.71% inhibition at 3 μmol/L GW0742; P<0.05) and the 
total distance (18.74% inhibition at 3 μmol/L GW0742; 
P<0.05) compared with vehicle-treated cells. Altogether, 
these data demonstrate that PPARδ ligands inhibit both 
proliferation and migration of VSMC through a receptor-
dependent mechanism.
Figure 1 Continued. aortas 42 d after stent deployment. Bar graphs showing reduced neointimal area, attenuated proliferation rate in the 
neointima and the underlying atherosclerotic lesion, and reduced neointimal vascular smooth muscle cell (VSMC) and macrophage con-
tent in vessels implanted with GW0742-Me–coated stents. D, Analysis of inflammatory gene expression (monocyte chemoattractant pro-
tein [MCP]-1, interleukin [IL]-6) by quantitative real-time polymerase chain reaction in stented (left) and nonstented arteries (right) artery 
segments. Results are presented as mean±SEM. *P<0.05 vs vehicle-coated stents, 1-way ANOVA with post hoc correction (Bonferroni). A 
indicates atheromatous core; M, media; N, neointima; and S, stent struts.
0.0
0.2
0.4
0.6
0.8
1.0
1.2
EtOH GW-Me
High Dose
GW-Me
Low Dose
N
eo
in
tim
a 
ar
ea
 (m
m
2 )
0
0.2
0.4
0.6
0.8
1
0
2
4
6
8
10
12
14
16
18
M
ed
ia
 a
re
a 
(m
m
2 )
A
th
er
os
cl
er
os
is
 p
ro
lif
er
at
io
n
(n
uc
le
i p
er
 m
m
2 )
EtOH GW-Me
High Dose
GW-Me
Low Dose
0
5
10
15
20
25
30
35
N
eo
in
tim
a 
pr
ol
ife
ra
tio
n
(n
uc
le
i p
er
 m
m
2 )
EtOH GW-Me
High Dose
GW-Me
Low Dose
EtOH GW-Me
High Dose
GW-Me
Low Dose
0
0.1
0.2
0.3
0.4
0.5
0.6
EtOH GW-Me
High Dose
GW-Me
Low Dose
N
eo
in
tim
al
 s
m
oo
th
 m
us
cl
e
ce
ll 
ar
ea
 (m
m
2 )
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
EtOH GW-Me
High Dose
GW-Me
Low Dose
N
eo
in
tim
al
 m
ac
ro
ph
ag
e
ce
ll 
ar
ea
 (m
m
2 )
*
*
*
*
*
*
*
*
*
*
0.0
0.2
0.4
0.6
0.8
1.0
1.2
EtOH GW-Me
high dose
0.0
0.2
0.4
0.6
0.8
1.0
1.2
EtOH GW-Me
high dose
GW-Me
low dose
M
C
P
-1
 m
R
N
A 
ex
pr
es
si
on
M
C
P
-1
 m
R
N
A 
ex
pr
es
si
on
0.0
0.2
0.4
0.6
0.8
1.0
1.2
GW-Me
low dose
EtOH GW-Me
high dose
GW-Me
low dose
IL
-6
 m
R
N
A 
ex
pr
es
si
on
0.0
0.2
0.4
0.6
0.8
1.0
1.2
IL
-6
 m
R
N
A 
ex
pr
es
si
on
EtOH GW-Me
high dose
GW-Me
low dose
*
*
Stented Artery Segments Non-Stented Artery Segments
C D
 by guest on A
ugust 9, 2017
http://atvb.ahajournals.org/
D
ow
nloaded from
 
Hytönen et al  PPARδ as Strategy to Improve DES Outcomes  5
Because VCMC proliferation and migration is associated 
with higher energy requirements, we examined the effect of 
GW0742 on both glycolytic flux (extracellular acidification 
rate) and mitochondrial oxygen consumption (oxygen con-
sumption rate) using extracellular flux technology. rVSMCs 
were incubated with 10 μmol/L GW074 or vehicle for 24 
A
B
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
Con Con3 µM 
PDGF PDGF
3 µM GW 
3 µM GW 3 µM GW 
- -
0
5000
10000
15000
20000
25000
30000
Con - 10 µM GW0.1 1
PDGF (20 ng/ml)
AT
P 
A
ss
ay
C
el
l n
um
be
r
fo
ld
 in
du
ct
io
n
PPARδ WT PPARδ KO
*
*
*
0
20
40
60
80
100
120
140
160
180
200
E
uc
lid
ea
n 
di
st
an
ce
Con
PDGF
-
0
100
200
300
400
500
600
700
To
ta
l d
is
ta
nc
e
Con
PDGF
-
PDGF PDGF + 3 µM GW-
*
*
Figure 2. Peroxisome proliferator–activated receptor-delta (PPARδ) activation inhibits growth and platelet-derived growth factor (PDGF)-
BB–directed migration of vascular smooth muscle cells (VSMCs). A, G1-arrested rat VSMC (rVSMC) and PPARδ
−/− and PPARδ+/+ mouse 
VSMCs (mVSMCs) resumed growth by treatment with PDGF-BB (20 ng/mL). Cells were preincubated with GW0742 (GW) for 24 h as indi-
cated before addition of mitogens. Cell proliferation of rVSMCs was determined using an ATP Assays (left). Proliferation of mVSMCs was 
assayed by counting the cells using a hematocymeter (right). B, The migration path of 30 representative rVSMC was plotted after normal-
izing the starting point to x=0 and y=0 (top). Red and black lines are cell tracks moving toward the PDGF-BB gradient or moving in other 
directions, respectively. Diagram shows analysis of euclidean distance and total distance of rVSMCs in the absence of the chemoattrac-
tant PDGF-BB (Con), with PDGF-BB alone and in the presence of PDGF-BB and GW0742. Data are presented as mean±SEM. *P<0.05 vs 
PDGF-stimulated cells, 1-way ANOVA with post hoc correction (Bonferroni).
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hours and changes in glycolysis in response to both acute 
(data not shown) and chronic PDGF-BB (24 hours) treatment 
were analyzed. As depicted in Figure 3A (left), PDGF addi-
tion increased extracellular acidification rate (3.93-fold versus 
unstimulated cells; P<0.05), which was significantly reduced 
in GW0742 pretreated rVSMCs (24.32% inhibition; P<0.05). 
Oligomycin was used to eliminate mitochondrial ATP produc-
tion, thus inducing maximal glycolytic response. GW0742 
(Figure 3A, right) significantly attenuated oligomycin-
induced increase in glycolysis (24.42% inhibition; P<0.05). 
Next, the effect of GW0742 on mitochondrial oxygen con-
sumption in both acute (data not shown) and chronic PDGF-
BB–treated rVSMCs was analyzed. Treatment with GW0742 
significantly decreased the maximal respiratory capacity with-
out PDGF-BB (32.34% inhibition; P<0.05; Figure 3B, left). 
ATP-linked respiration was maintained during PDGF-BB 
treatment and compromised by GW0742 in the absence of 
PDGF-BB (ATP-linked respiration: basal minus oligomy-
cin [proton leak] respiration; 23.03% inhibition; P<0.05; 
Figure 3C). As GW0742 increased mitochondrial proton leak 
respiration (measured after oligomycin addition; Figure 3B, 
center), the reserve respiratory capacity was almost abolished 
on GW0742 treatment without PDGF-BB (Figure 3B, right) 
to maintain ATP production. Taken together oxidative phos-
phorylation and glycolysis, PDGF enhances energy metabo-
lism by increasing glycolysis and shifting ATP production 
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Figure 3. Peroxisome proliferator–activated receptor-delta (PPARδ) activation attenuates glycolytic flux and mitochondrial respiration. A, 
PPARδ activation attenuates platelet-derived growth factor (PDGF)–induced (left) and oligomycin-induced (right) increase of extracellular 
acidification rate (ECAR). Rat VSMCs (rVSMC), incubated with 10 μmol/L GW0742 or vehicle (DMSO), were stimulated with or without 
platelet-derived growth factor (PDGF)-BB (25 ng/mL) for 24 h, and ECAR was measured over time. Oligomycin (2 µg/mL) was injected to 
determine the glycolytic response to inhibition of mitochondrial ATP synthesis. B, PPARδ activation reduces the maximal reserve capacity 
(left), protone leak (middle), and mitochondrial reserve capacity (right) in unstimulated and PDGF-treated rVSMCs. C, PPARδ activa-
tion decreases the coupling efficiency in unstimulated and PDGF-treated rVSMCs. The measurements were normalized to the total cell 
number determined by DAPI staining. D, PPARδ activation induces adenosine 5′-monophosphate-activated protein kinase (AMPK) phos-
phorylation in rVSMCs. E, rVSMCs were treated with vehicle (DMSO) or PPARδ ligand GW0742 (10 μmol/L) for 24 h. Total RNA was iso-
lated and pyruvate dehydrogenase kinase isozyme 4 (PDK4) and Glut1 mRNA was measured by quantitative real-time polymerase chain 
reaction (PCR). Results are presented as mean±SEM. *P<0.05 compared with control; #P<0.05 compared with PDGF-BB, 1-way ANOVA 
with post hoc correction (Bonferroni).
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toward glycolysis (Warburg-like effect). GW0742 attenuates 
glycolytic pathways and reduces the metabolic scope of mito-
chondria by decreasing spare respiratory capacity.
The adenosine 5′-monophosphate-activated protein 
kinase (AMPK) is a key metabolic sensor that responds 
to cellular energy deprivation by inhibiting ATP-depleting 
processes and ATP-promoting processes that increase ATP 
synthesis within the cell.23 This prompted us to investi-
gate whether PPARδ ligands induce AMPK phosphoryla-
tion. As shown in Figure 3D, stimulation of rVSMCs with 
GW0742 dose-dependently induced AMPK phosphorylation 
at threonine 172.
To further characterize the role of PPARδ in energy metab-
olism, rVSMCs were stimulated with GW0742 and metabolic 
gene regulation was analyzed. As shown in Figure 3E, PPARδ 
ligand treatment induces expression of pyruvate dehydroge-
nase kinase isozyme 4 mRNA (7.74-fold versus unstimulated 
cells; P<0.05), whereas the expression of key regulators of 
fatty acid transport (Fabp3) and oxidation (Cpt1b, SCD1, 
SCD2, Acsl1, and Acot1) were unaltered by GW0742 treat-
ment (data not shown). In contrast, the expression of GLUT1, 
the predominant glucose transporter protein in VSMCs,24 was 
markedly downregulated (36.0% inhibition; P<0.05).
PPARδ Activation Suppresses Cytokine-Induced 
Inflammatory Gene Expression in VSMCs
Because inflammation is a key component in in-stent reste-
notic lesion formation,25 we analyzed the function of PPARδ 
in VSMCs in this process. To determine the effect of syn-
thetic PPARδ ligands on cytokine-induced inflammatory gene 
expression, quiescent rVSMCs, pretreated with GW0742 for 
24 hours, were stimulated with tumor necrosis factor-α (10 
ng/mL) for additional 8 hours. As depicted in Figure 4A, 
PPARδ ligand inhibits tumor necrosis factor-α–stimulated 
IL-6, MCP-1, and VCAM mRNA expression in a dose-
dependent manner (at 10 μmol/L GW0742 64.69% inhibi-
tion of IL-6; 69.0% inhibition of MCP-1; 75.83% inhibition 
of VCAM versus tumor necrosis factor-α alone; P<0.05). We 
next used mouse VSMCs isolated from the aorta of PPARδ+/+ 
and PPARδ−/− mice to further address whether the observed 
inhibitory effect is mediated by PPARδ. The inhibitory effect 
of GW0742 (Figure 4B) on inflammatory gene expression in 
PPARδ wild-type mouse VSMCs was completely abolished 
in PPARδ knockout cells, demonstrating that PPARδ ligands 
repress IL-6, MCP-1, and VCAM through a receptor-depen-
dent mechanism.
Previous studies indicate that, in the absence of a spe-
cific ligand, PPARδ binds the transcriptional repressor B-cell 
lymphoma 6 (Bcl-6) and PPARδ ligand binding causes a dis-
sociation of Bcl-6 from PPARδ.26 This interaction prompted 
us to address the role of Bcl-6 in regulating inflammatory 
gene expression in VSMCs. Therefore, we transiently trans-
fected rVSMCs with a Bcl-6 overexpression vector. As shown 
in Figure 4C, Bcl-6 overexpression resulted in a significant 
inhibition of IL-6, MCP-1, and VCAM mRNA expression in 
rVSMCs. We next performed chromatin immunoprecipitation 
assays to determine whether PPARδ ligand treatment induces 
Bcl-6 binding to the endogenous IL-6, MCP-1, and VCAM 
promoter. Using primer pairs that cover regions in the proxi-
mal IL-6, MCP-1, or VCAM promoter, we demonstrate that 
PPARδ ligand treatment induces Bcl-6 binding to the corre-
sponding inflammatory gene promoter sequences (Figure 4D). 
Together, these data show that PPARδ ligand treatment of 
VSMCs induces a dissociation of Bcl-6 from PPARδ and sub-
sequent binding to specific regions within inflammatory gene 
promoters, thus inhibiting corresponding gene expression.
PPARδ Ligand Inhibits Thrombocyte 
Activation and Aggregation
Platelets not only are essential to hemostasis and thrombosis but 
also activate immune cells and mediate inflammation.27 Although 
platelets contain no nucleus, many nuclear receptors were found 
to be expressed in platelets including all 3 PPAR subtypes and 
their binding partner retinoid X receptor.28–30 Thus, we investi-
gated the effect of PPARδ ligand on thrombocyte activation and 
aggregation in vitro. Consistent with the previous observation,29 
PPARδ was expressed in human platelets (Figure 5A). PPARδ 
ligand GW0742 dose-dependently inhibited ristocetin (0.75 μg/
mL)–induced maximal aggregation (56.13% inhibition at 100 
μmol/L GW0742) and maximal aggregation velocity (55.77% 
inhibition at 100 μmol/L GW0742) of human platelets in 
vitro. However, GW0742 did not affect collagen-induced 
platelet aggregation (data not shown).
We next performed activation assays in platelets isolated 
from PPARδ−/− and age-matched controls. Notably, GW0742 
significantly attenuated ADP-induced thrombocyte aggrega-
tion in PPARδ+/+ platelets (28.38% inhibition at 10 μmol/L 
GW0742), whereas no effect was observed in PPARδ-
depleted platelets (Figure 5B). Interestingly, ADP-induced 
thrombocyte aggregation was attenuated in PPARδ knockout 
compared with wild-type platelets.
To investigate the effect of PPARδ ligand–coated stents on 
thrombocyte activation and aggregation, GW0742-Me– and 
vehicle (ethanol)–coated stents were implanted in a low-grade 
thrombogenic closed-loop system and perfused with human 
platelet-rich plasma at shear rates far below the threshold 
value at which activation of platelets occurs.31 Number of cir-
culating platelets, glycoprotein (GP) Ib and IIb/IIIa expression 
and activation (PAC-1 binding), P-selectin (CD62) and CD63 
expression were evaluated before and after 1, 11, and 21 cir-
culations (Figure 5D). The number of single circulating plate-
lets was significantly reduced by 15.2% after 21 circulations 
(P<0.05) of vehicle-coated stents, whereas no effect on plate-
let number was observed with PPARδ ligand–coated stents. 
In contrast to GW0742-Me–coated stents, the platelet reac-
tivity index increased after perfusion of vehicle-coated stents 
by 12.3% (P<0.05), indicating that the decrease in circulating 
platelets is attributable to an increased adherence to the stent, 
rather than to aggregate formation. In accordance, platelet 
thrombi were observed between struts of vehicle-coated stents 
(Figure 5C), but not between struts of GW0742-Me–coated 
stents. As determined by flow cytometry, the density of GP Ib 
receptor per platelet was significantly reduced in the vehicle-
coated stent group (–12.4%; P<0.05) but remained unchanged 
in the GW0742-Me–coated stent group. After 21 circulations, 
the density of GP IIb/IIIa and the number of PAC-1–positive 
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platelets were increased with vehicle-coated stents by 13% 
and 6.9% (both P<0.05), indicating thrombocyte activation. 
In contrast, in GW0742-Me–coated stents, no changes in the 
expression of GP IIb/IIIa and PAC-1 on the platelet surface 
was observed. Finally, the concentration of the thrombin–anti-
thrombin III complex, indicating an activation of the coagula-
tion system, was significantly increased in the vehicle-coated 
group after 21 circulations (+37.9%; P<0.05), but remained 
unchanged in the GW0742-Me–coated group (data not 
shown). The fraction of CD62- and CD63-positive platelets 
did not differ among the groups (data not shown).
PPARδ Activation Induces Human Umbilical Vein 
Endothelial Cell Proliferation and Migration
PPARδ regulates EC proliferation, angiogenesis, and EC sur-
vival.32 However, the role of PPARδ in ECs is controversial, as 
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Figure 4. Peroxisome proliferator–activated receptor-delta (PPARδ) activation inhibits tumor necrosis factor (TNF)-α–induced inflamma-
tory gene expression in G1-arrested rat vascular smooth muscle cell (rVSMC) (A) and PPARδ
+/+ mouse VSMCs (B). Serum-deprived cells 
were pretreated with vehicle (DMSO) or the indicated concentrations of PPARδ ligand GW0742 (GW) for 24 h, followed by stimulation with 
TNFα (10 ng/mL). Total RNA was isolated and interleukin (IL)-6, monocyte chemoattractant protein (MCP)-1, and VCAM mRNA expression 
was measured by quantitative real-time polymerase chain reaction (PCR). C, Overexpression of Bcl-6 attenuates IL-6, MCP-1, and VCAM 
mRNA expression in rVSMCs. Cells were transiently transfected with a Bcl-6 expression vector or an empty control vector (pcDNA3.1). 
At 24 h after transfection, cells were serum starved followed by TNFα (10 ng/mL) stimulation. Total RNA was isolated, and IL-6, MCP-1, 
and VCAM expressions were analyzed by quantitative real-time RT-PCR. D, PPARδ ligands induce Bcl-6 binding to the IL-6, MCP-1, and 
VCAM promoter. Chromatin immunoprecipitation assays were performed on chromatin isolated from serum-deprived rVSMCs treated with 
vehicle (DMSO) or GW0742 (10 μmol/L) and stimulated with TNFα (10 ng/mL). All experiments were repeated at least 3 times with different 
cell preparations of primary VSMCs. Data are expressed as fold induction±SEM over unstimulated control (Con). *P<0.05 vs TNFα-treated 
cells, 1-way ANOVA with post hoc correction (Bonferroni) or Student t test, as appropriate. KO indicates knockout; and WT, wild-type.
 by guest on A
ugust 9, 2017
http://atvb.ahajournals.org/
D
ow
nloaded from
 
Hytönen et al  PPARδ as Strategy to Improve DES Outcomes  9
both an inhibition and induction of EC proliferation and angio-
genesis on PPARδ ligand stimulation has been reported.33,34
Treatment of primary human umbilical vein endothelial 
cells (HUVECs) with PPARδ ligand (1 μmol/L GW0742) 
increased EC number (1.17-fold versus unstimulated con-
trol), whereas both sirolimus and tacrolimus attenuated 
HUVEC proliferation compared with untreated control cells 
(24.09% inhibition at 10 nmol/L sirolimus (36.42% inhibi-
tion at 20 μmol/L tacrolimus; P<0.05; Figure 6A). To ana-
lyze chemotaxis of HUVECs, vehicle-treated (DMSO) or 
GW0742-treated cells were allowed to migrate in the pres-
ence of a VEGF gradient. Cell tracks were recorded by 
time-lapse microscopy, and the Euclidean distance and total 
distance were analyzed. GW0742 treatment significantly 
enhanced the chemotaxis of HUVECs compared with vehi-
cle-treated cells (Figure 6B). To analyze the effect of PPARδ 
ligands on cell attachment and spreading dynamics, we used 
the xCELLigence System. As shown in Figure 6C, GW0742 
increased adhesion and spreading of HUVECs when com-
pared with untreated cells.
Vascular Injury Induces PPARδ Expression in Rat 
Carotid Arteries and Human Coronary Arteries
As shown in Figure 7A, PPARδ expression was upregulated 
in the neointima 14 days after carotid artery balloon injury in 
3-month-old Sprague–Dawley rats. Similar to the rat carotid 
artery injury model, we observed increased PPARδ expres-
sion in human coronary arteries after PCI. At 2 weeks after 
stenting, the stent struts were covered by neointimal tissue, 
composed mainly of VSMCs with infiltrating macrophages. 
At this time point, PPARδ expression was highly upregulated 
in the neointima in both macrophages and VSMCs compared 
with the underlying atherosclerotic lesion. In contrast, 2 days 
after PCI without stent placement and 3 years after stenting, 
only weak PPARδ expression was detected in the atheroscle-
rotic lesions and neointimal areas (Figure 7B and 7C).
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Figure 5. Peroxisome proliferator–activated receptor-delta (PPARδ) activation inhibits thrombocyte activation and aggregation. A, PPARδ 
ligand GW0742 (GW) inhibits ristocetin-induced maximal aggregation (left) and maximal aggregation velocity (right) of human plate-
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stents (n=6 per group) were implanted in a closed-loop system and perfused with human platelet-rich plasma. Raster electron microscopy 
reveals formation of thrombi between vehicle (EtOH)–coated stent struts after 21 circulations (C). Thrombocyte activation and aggregation 
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Discussion
We demonstrate that PPARδ ligand–coated stents strongly 
reduce neointima formation in a rabbit model of experimen-
tal atherosclerosis. We attribute this effect to an inhibition 
of VSMC proliferation, reduced migration, and down-
regulated inflammatory gene expression. Furthermore, 
we observed an attenuation of thrombocyte activation and 
aggregation, as well as an induction of EC adhesion, pro-
liferation, and chemotaxis according to the mechanistic 
schema that we suggest (Figure VI in the online-only Data 
Supplement).
The neointima in our rabbit model of experimental ath-
erosclerosis closely mimicked the angioplasty processes in 
humans, as stents are implanted in preformed atheroscle-
rotic lesions. Aside from stent design, the rate and duration 
of drug release from the stent and the accumulation of drug 
in the vessel wall plays an important role in arterial heal-
ing.35 As high-performance liquid chromatography–based 
analysis depicted an ≈100% GW0742 release from coated 
stents in vitro within 15 minutes, we modified the solubil-
ity of GW074 by methylester conjugation. Using GW0742-
Me–coated stents, we achieved a sustained drug release and 
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intramural deposition both in vitro and in vivo. We show 
that GW0742-Me–coated stents markedly reduce neointima 
formation and luminal narrowing both 14 and 42 days after 
stent placement. This result was accompanied by a signifi-
cant reduction in cell proliferation both in the neointima and 
in the underlying atherosclerotic lesion. In addition, stent 
coating with GW0742-Me strongly attenuates inflammatory 
gene expression in the underlying vessel wall. However, a 
limitation of our study is the lack of a comparison with a 
commercially available DES. We also analyzed thrombocyte 
deposition 14 days after stent placement (data not shown). 
However, thrombocyte deposition to uncovered stent struts 
14 days after placement of vehicle or GW0742-Me–coated 
stents was rare, as adhesion of platelets to the endolumi-
nal side of the stents occurs early after stent deployment.36 
Interestingly, whereas our in vitro experiments clearly show 
a dose-dependent and PPARδ receptor–mediated effect of 
PPARδ ligands, in vivo the attenuation of neointima forma-
tion was more effective with low-dose GW0742-Me–coated 
stents. We cannot exclude that the inverse dose-dependent 
effect of PPARδ ligand (GW0742-Me)–coated stents on 
neointima formation comes from PPARδ receptor–inde-
pendent modes of action such as activation or inhibition 
of other nuclear receptors. Thus Nandhikonda et al37 previ-
ously reported that GW0742 exhibits characteristics of a pan 
nuclear receptor antagonist at high concentrations. In addi-
tion, differences in neointima formation could represent local 
toxicity caused by high-dose GW0742-Me–coated stents. 
Moreover, in our study, stents were not examined beyond 42 
days, thus precluding assessment of possibly different long-
term effect of high-dose and low-dose GW0742-Me–coated 
stents on neointima formation.
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Figure 7. Peroxisome proliferator–activated receptor-delta (PPARδ) expression is highly upregulated in rat and human neointima. A, Rep-
resentative photomicrographs of histological cross sections of balloon-injured rat carotid arteries demonstrate strong PPARδ immunore-
activity in the neointima with weak staining in the media 2 wk after injury (n=8 per group). Arrows indicate the internal elastic lamina (IEL). 
B and C, Serial sections of a human nonstented left anterior descending coronary artery 2 d after PTCA (no stent; left), a left anterior 
descending coronary artery 2 wk after stenting (middle) and a left circumflex coronary artery 3 y after stenting (right). B, Toluidine blue 
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In-stent restenosis and bypass graft failure are character-
ized by excessive VSMC proliferation, leading to luminal 
narrowing. However, data on the role of PPARδ in modu-
lating cell proliferation are controversial, as both increased 
and decreased cell proliferation rates by synthetic PPARδ 
ligands have been reported previously.19,38 Whereas Lim et 
al19 reported that adenovirus-mediated overexpression of 
PPARδ suppresses PDGF-induced VSMC proliferation, 
Zhang et al39 found that overexpression of PPARδ in VSMCs 
increases postconfluent cell proliferation. In addition, Lim 
et al used L-165041, the first synthetic compound that not 
only activates PPARδ, but also triggers PPARγ activation at 
high doses.40 As the role of the nuclear receptor PPARδ in 
mediating the opposite growth modulatory effects of PPARδ 
ligands on various cell types has not clearly been defined, we 
analyzed the effect of GW0742 on both normal and PPARδ-
depleted VSMCs. Our data indicate that the PPARδ ligand 
GW0742 inhibits proliferation and migration of VSMCs in 
vitro in a PPARδ receptor–dependent manner. Given the 
increased energy requirements for cell proliferation and 
chemotaxis, we examined the effect of the synthetic PPARδ 
agonist GW0742 on glycolysis and mitochondrial respira-
tion using extracellular flux analysis. Consistent with previ-
ously published studies,11 our data demonstrate that PDGF 
stimulation enhances glycolysis in VSMCs. We found that 
under both acute and chronic treatment conditions, GW0742 
inhibits PDGF-induced augmentation of glycolysis. In addi-
tion, GW0742 treatment significantly attenuates the maxi-
mal respiratory capacity and the reserve respiratory capacity 
and increases the mitochondrial proton leak respiration. The 
observed effect of GW0742 on PDGF-induced glycolysis and 
mitochondrial respiration impairs the ability of VSMCs to 
provide the increased energy demands required for growth 
factor–stimulated proliferation and migration of VSMCs. 
PPARδ activation is known to regulate many genes involved 
in fatty acid and glucose utilization.41 However, data about 
the effect of PPARδ ligands on glucose metabolism are con-
troversial, as both impaired and increased glucose utilization 
has been reported.42,43 Our data show that GW0742 treatment 
strongly induces pyruvate dehydrogenase kinase isozyme 4 
in VSMCs. Pyruvate dehydrogenase kinase isozyme 4 phos-
phorylates and inactivates pyruvate dehydrogenase, which 
inhibits the utilization of pyruvate for acetyl-CoA synthesis 
and thus blocks glucose oxidation. In addition, we found 
that the expression of GLUT1, the predominant isoform of 
glucose transporter proteins in VSMCs,24 was significantly 
reduced in response to GW0742 treatment.
The signaling pathways that link changes in VSMC 
energy metabolism and function are poorly understood. 
Recently, AMPK emerged as important regulator of meta-
bolic processes and VSMC migration and proliferation.44 Our 
data demonstrate that GW0742 treatment of VSMCs induces 
AMPK phosphorylation of the catalytic α domain at threo-
nine 172. AMPK is a key metabolic sensor that is phosphory-
lated in response to cellular energy deprivation and stress45 
and acts to restore energy homeostasis by switching off ATP-
consuming processes and switching on catabolic pathways 
that generate ATP. However, the relationship of AMPK in 
PPARδ-mediated inhibition of cell proliferation is complex. 
As AMPK activation in skeletal muscle was previously found 
to be PPARδ independent,43 the observed induction of AMPK 
phosphorylation in VSMCs after GW0742 treatment is likely 
either because of the change in cellular energy metabolism 
or mediated directly via heme oxygenase-1 (Figure IV in the 
online-only Data Supplement). In accordance, Kim et al46 
recently observed that heme oxygenase-1 induces activation 
of AMPK in VSMCs.
The inflammatory response of VSMCs plays an important 
role in neointima formation after PCI. Our data demonstrate 
that PPARδ ligands inhibit tumor necrosis factor-α–induced 
expression of IL-6, MCP-1, and VCAM by inducing Bcl-6 
binding to the corresponding inflammatory gene promoter 
sequence. Early studies indicate that PPARγ is not required 
for the anti-inflammatory effect of its ligands.47 However, 
by use of primary cultures of VSMCs from wild-type and 
PPARδ−/− mice, we demonstrate that PPARδ ligands inhibit 
inflammatory gene expression in a receptor-dependent man-
ner. Taken together, GW0742 affects crucial biological 
VSMC functions, including proliferation and gene expres-
sion, which is compatible with beneficial outcome in experi-
mental restenosis.
The interaction of platelets with the surface of DES plays 
an important role in both in-stent restenosis and stent throm-
bosis. Thrombocyte adhesion and aggregation is mediated 
by a variety of surface glycoproteins such as GP IIb/IIIa, GP 
VI, or the GP Ib–IX–V complex.48 On Upon activation, GP 
IIb/IIIa undergoes a conformational change, and additional 
intraplatelet pools of GP IIb/IIIa are released that increase the 
surface density. In addition, von Willebrand factor plays an 
important role in platelet adhesion at the site of endothelial 
injury, as it mediates platelet–subendothelium interaction by 
linking the platelet receptor GP Ib–IX–X to the extracellular 
matrix.49 To date, no stent coating with an antithrombotic effect 
has been developed. Strikingly, we found that GW0742-Me 
coating effectively prevents human thrombocyte deposition 
to the stents surface and thrombocyte activation in vitro. As 
determined by flow cytometry, both platelet surface receptor 
GP IIb/IIIa surface density and activation (PAC-1 binding) 
increased after perfusion of vehicle-coated stents, whereas 
no change was observed with GW0742-Me–coated stents. 
In addition, perfusion of vehicle-coated stents increased the 
thrombin–antithrombin III values, indicating the thrombin 
generation of adhering activated platelets, which leads to the 
activation of the plasmatic coagulation. The density of GP Ib 
receptor per platelet was significantly reduced in the vehicle-
coated stent group, which reflects a higher activation in the 
closed-loop system.50 Furthermore, PPARδ ligand GW0742 
dose-dependently inhibited ristocetin-induced human throm-
bocyte aggregation in vitro, whereas no effect was observed 
on collagen-induced platelet aggregation at a concentration of 
5 μg/mL. Both ristocetin and collagen induce platelet aggre-
gation via common pathways such as activation of phospho-
lipase C (PLC). However, as ristocetin forms a complex with 
von Willebrand factor that facilitates binding to the GP Ib–
IX–V complex, the specific inhibition of ristocetin-induced 
platelet aggregation by GW0742 could be attributed to an 
inhibition or dissociation of the von Willebrand factor—GP 
Ib–IX–V complex.
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In contrast to our observation, Ali et al29 reported in 
2006 that PPARδ ligands (L-165041; GW0742) inhibit 
human platelet activation induced by various stimuli such 
as collagen, thrombin, and ADP. However, in this study, 
measurements were performed in whole-blood and higher 
concentrations of both the agonists and the PPARδ ligand 
GW0742 were used, which might explain the different 
results. Thus, it was recently reported that nitrite inhibits 
P-selectin expression on the platelet membrane and GP IIb/
IIIa activation in response to ADP, collagen, and thrombin 
stimulation in the presence of erythrocytes, and this inhi-
bition was promoted by increasing hematocrit and deoxy-
genation of erythrocytes (what takes place during storage), 
suggesting that NO produced by the reaction of nitrite 
with deoxyhemoglobin was responsible for this inhibitory 
effect.51 Whereas a previous study reported that the abil-
ity of PPARδ agonist GW501516 to inhibit ADP-induced 
platelet aggregation was similar in PPARδ−/− and PPARδ+/+ 
mouse thrombocytes,52 our data demonstrate that GW0742 
mediated inhibition of thrombocyte aggregation is receptor 
dependent, as the effect was abolished in PPARδ−/− plate-
lets. In summary, differences between previous reports and 
our results might be attributed to a variety of different fac-
tors, including different specificities of PPARδ agonists for 
other PPAR isoforms, different potencies of various PPARδ 
compounds, different in vitro conditions (whole-blood ver-
sus platelet-rich plasma), or use of different PPARδ knock-
out mouse models.
Recent studies indicate that a rapid re-endothelialization of 
the stented area is associated with a lower risk of inflammation 
and subsequent thrombus formation.53 A major concern with 
currently used DES is impaired re-endothelialization because 
of the drug.54 Endothelial regrowth after stenting depends on 
both migration from intact neighboring coronary segments, 
and attraction and adhesion of circulating endothelial progeni-
tor cells. Previous studies have shown that sirolimus and pacli-
taxel inhibit proliferation and migration of ECs in vitro,55,56 
thereby potentially impairing re-endothelialization. Data on 
the role of PPARδ in ECs are controversial, as both propro-
liferative and antiproliferative effects have been reported.33,34 
Our data demonstrate that GW0742 induces proliferation and 
VEGF-induced migration of cultured ECs. In addition, adhe-
sion and spreading, essential processes for EC migration, 
were accelerated in GW0742-treated ECs. However, in our 
rabbit model of experimental atherosclerosis, no difference in 
re-endothelialization was evident with the use of GW0742-
coated stents compared with vehicle-coated stents as endothe-
lial regrowth was already almost complete at day 14 (Figure V 
in the online-only Data Supplement). Although animal models 
of stenting probably predict human responses as the stages of 
healing are remarkably similar, previous studies have shown 
that endothelial regrowth is significantly more rapid in the rab-
bit model than in the humans, where re-endothelialization is 
only complete by 3 to 4 months after bare-metal stent implan-
tation or may even not fully endothelialize several years 
after implantation.6,57 We did not clearly define the underly-
ing mechanism responsible for the contrary effect of PPARδ 
activation by synthetic ligands on proliferation/migration of 
VSMCs and ECs. However, we can speculate that the different 
effect of PPARδ on proliferation of VSMCs and EC comes 
from cell-type–specific expression levels of coactivators and 
corepressors, differences in post-translational modifications 
and proteosomal degradation of PPARδ.
In conclusion, our data demonstrate that PPARδ ligand–
coated stents lead to significant inhibition of in-stent neo-
intima formation compared with vehicle-coated stents. We 
attribute this effect to an inhibition of VSMC proliferation and 
inflammatory gene expression and potentially an inhibition of 
thrombocyte activation and a proproliferative and promigra-
tory effect on ECs. Thus, PPARδ ligand–coated stents might 
be a promising strategy to address the problems of in-stent 
restenosis and late-stent thrombosis. Further preclinical stud-
ies and clinical trials are needed to test this hypothesis.
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1 
 
SUPPLEMENTAL MATERIAL 
 
MATERIAL AND METHODS 
Materials 
Antibodies were purchased from the following suppliers: p-AMPK alpha and total AMPK alpha 
from Cell Signaling, Bcl-6 from Santa Cruz Biotechnology, PPARδ (sc-1987) and PECAM-1 (sc-
1506) from Santa Cruz Biotechnology, anti-rabbit macrophage (clone RAM11) and Ki67 (clone 
Ki-67) from Dako, smooth muscle actin (clone HHF35) and CD68 from Thermo ScientificTM Lab 
Vision. The anti-topoisomerase II (clone KiS1) was kindly provided by Prof. Wolfram Klapper 
(University Clinic Kiel, Germany). The Bcl-6 expression plasmid was kindly provided from Ari 
Melnick (Weill Cornell Medical College, NY, USA) and the HO-1 promoter constructs were 
generously provided by Mark Perella (Brigham and Women’s Hospital, Boston, USA). PPARδ 
knockout and wildtype mice were kindly provided by Frank J. Gonzalez (National Cancer 
Institute, Rockville, USA). GW0742 was provided by Dr. Timothy M. Willson (GlaxoSmithKline 
Inc, Durham, NC). 
 
Human Coronary Samples 
Stented coronary artery segments were obtained during autopsy at the Institute for Pathology of 
the University Hospital of Hamburg. A total of 21 samples were collected 3 hours to 3 years after 
stenting from 6 patients. In addition, 3 samples from a nonstented coronary artery were 
analyzed.(1) The protocol was approved by the ethics committee of the University Hospital of 
Hamburg. 
 
Rabbit Model of Experimental Atherosclerosis 
The study was approved by the University of Kuopio Research Animal Ethics Committee and 
conforms to National Institutes of health guidelines. A rabbit model of experimental 
atherosclerosis was used as previously described.(2, 3) Briefly, 46 New Zealand white rabbits 
(3.0 to 4.0 kg; Lidkoeping Kaninfarm, Sweden) were fed an atherogenic diet consisting of 1% 
cholesterol and 6% peanut oil for 5 weeks. After one week of high cholesterol diet, a 3-French 
Fogarty embolectomy catheter was advanced into the right iliac artery and aorta and withdrawn 
with the balloon inflated. After aortic denudation, the animals were maintained on an atherogenic 
diet for additional 4 weeks before stent implantation. Subsequent, the diet was switched to a low 
cholesterol diet (containing 0.025% cholesterol). Blood samples were drawn at the time of aortic 
denudation, at the end of the atherogenic diet, before stent deployment and at euthanasia for 
determination of the differential blood count and measurement of various serum parameters. 
Animals were kept on a 12/12 hour-dark cycle with ad libitum access to food and water. 
 
Stent Coating 
Polymer-free stents (YUKON®ChoiceDES, 20 x 3.5 mm, Translumina GmbH) were coated with 
the methylester conjugated PPARδ ligand GW0742 (GW0742-Me). GW0742-Me was prepared 
treating GW0742 (100 mg/ 6 ml ethanol) with an excess of ethereal diazomethane until the 
yellow color of diazomethane persisted. After 20 min at room temperature, the remaining 
diazomethane and solvent were removed under reduced pressure. This reaction resulted in a 
complete conversion of GW0742 to its methylester as proved by reversed-phase HPLC. For 
stent coating, the cartridge was placed into the stent coating device and a 1 ml drug reservoir 
containing the dissolved drug in a predefined volume was connected to the cartridge. The 
coating process was initialized by the advancement of the drug into a mobile, positionable ring 
containing three jet units, which allow for uniform delivery of the drug onto the stent surface. For 
low-dose coating, the spray solution contained 4.5 mg GW0742-Me/ml ethanol. High-dose 
coating was achieved by spraying the stents twice with 7.5 mg GW0742-Me/ml ethanol. 
Subsequently to spray coating, the stent surface was dried by removing the ethanol with 
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pressured air. Any potentially remaining ethanol vaporizes after storage for one or two days 
according to the stent manufacturer Translumina®. To estimate the amount of GW0742-Me 
bound to the stent surface, three stents of each the low- and high-dose group were used and the 
compound was eluted with 5 and 20 ml of ethanol, respectively. The eluted GW0742-Me was 
determined spectrophotometrically using its characteristic absorption maxima at 232 and 318 nm 
and corresponding linear calibration curves with the authentic standard compound. Based on 
these measurements, 151.2 ± 15.4 µg and 445.3 ± 61.2 µg GW0742 were bound to the stent 
surface after low- and high-dose coating, respectively. Covering of the stent surface with the 
GW0742-Me coating was analyzed using electron scanning microcopy (Zeiss DSM 962, 
Germany).   
 
Stent Placement and Tissue Harvest 
After induction of general anesthesia and heparinization (150 IU/kg), a 5-French arterial 
introducing sheath was placed into the left carotid artery. PPARδ ligand (GW0742-Me) or vehicle 
(ethanol) coated stents were deployed in an infrarenal aortic segment free of side branches and 
dilated by inflation to their nominal pressure (9 to 11 atm, 30 sec balloon inflation). After stent 
implantation, an angiography was performed to document vessel patency and exclude a 
dissection. All animals received aspirin from day 3 and clopidogrel from day 1 before the stent 
implantation until euthanasia. Fourteen days and forty-two days after stent deployment animals 
were euthanized and stented sites were excised for mRNA, immunohistochemical, and 
morphometric analyses. In addition, a 3-mm arterial segment proximal to the stents was 
processed to evaluate for edge effects.  
 
Immunhistochemistry and Morphometric Analyses 
The stented rabbit aortas and human coronary arteries were collected, fixed en bloc in 4% 
neutral buffered formalin, and dehydrated with a graded series of alcohol before embedding in 
methylmethacrylate (MMA) as previously described.(1) For immunohistochemistry, sections 
were deplastinized and stained with antibodies recognizing macrophages (CD68 or Ram11), 
HHF35 to detect smooth muscle cells, CD31 or PECAM-1 to quantify re-endothelialization, and 
to KiS1 or Ki67 to assess proliferation. Deplastination was carried out in 2-methoxyethyl acetate 
for 45 to 90 min. For toluidine blue staining sections without deplastination were used. 
Quantitative measurements of the neointima and media were made on cross-sectioned rabbit 
aortas stained with toluidine blue. Cell proliferation was assessed by counting Ki67-positive 
cells, macrophage and smooth muscle content was determined using computer assisted 
morphometry (Zeiss Axiovision). Paraffin embedding and immunohistochemistry of rat carotid 
arteries were performed as described previously.(4) Controls for immunostaining included 
stainings in which the primary antibody was omitted. 
 
Cell Culture 
Human umbilical vein endothelial cells (HUVECs) were commercially obtained (Lonza, USA) and 
expanded in EBM-2 supplemented with the EGMTM-2 BulletkitTM according to the manufacturer 
instructions for 3 to 5 passages. Mouse primary aortic VSMCs (mVSMCs) were prepared from 
aortas of 8- to 12-week old PPARδ+/+ or PPARδ-/- mice as described.(5) Rat aortic VSMCs 
(rVSMCs) were isolated as previously described.(6) Both mVSMCs and rVSMCs were 
maintained and passaged in DMEM supplemented with 10% fetal bovine serum (FBS), L-
glutamine (200 mmol/L) and 1% penicillin/streptomycin. In all experiments, VSMCs of passage 
four to ten were subjected to G0/G1 phase synchronization by starvation for at least 24 hours in 
medium containing 0.2% FBS. Cells were pretreated for 24 hours with the indicated doses of 
PPARδ ligand (GW0742) or vehicle (DMSO) prior to stimulation with PDGF-BB (25 ng/ml) or 
TNFα (10 ng/ml). Cell viability was measured using a commercially available MTT assay. 
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GW0742 exhibited no effect on cell viability (data not shown). All experiments were repeated at 
least three times with different cell preparations.  
 
Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction 
Total RNA isolation was performed using the RNeasy MINI Kit (QUIAGEN), and RNA was 
reverse transcribed with random hexamers using the TaqMan Reverse Transcription Reagent 
Kit (Applied Biosystems) according to the manufacturer’s instructions. Transcript levels of target 
genes were assessed using an iQ5 real-time PCR Detection System (Bio-Rad). Each sample 
was analyzed in triplicate and mRNA levels of glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH) were quantified and used as housekeeping gene in human and murine cells, 
respectively. Primer and probes in the experiments were obtained from Applied Biosystems. 
 
Protein Assays 
Western blots were performed as previously described.(4) Briefly, cells were harvested at the 
indicated time points and sonicated in solubilization buffer (Cell Signaling). Whole cell lysates 
were cleared by centrifugation, protein concentrations were determined by Lowry assay (Bio-
Rad) and equal amount of proteins were resolved by SDS-page. 
 
Cell Proliferation Assays 
Mouse and rat VSMCs were serum-deprived for at least 24 hours and incubated with the PPARδ 
ligand GW0742 as indicated. After stimulation with PDGF-BB (25 ng/ml), cell proliferation was 
assessed by cell counting using a hematocytometer or an ATP assay, as previously 
described.(4) HUVECs were seeded and grown for 48 hours in the absence or presence of 
sirolimus (10 nM), tacrolimus (20 µM) or GW0742 (1 µM).  
 
Two-dimensional Chemotaxis Assay 
Directional cell migration was examined using the µ-Slides from Ibidi (Ibidi, Germany) according 
to the manufacturer’s instructions. Briefly, cells were seeded into the center of a µ-Slide 
chamber and incubated for 2 hours until cells were attached. After cells were washed with 
medium to remove non-adherent cells PDGF-BB (25 ng/ml) or VEGF (50 ng/ml) was added as 
chemoattractant for rVSMCs or HUVECs respectively. Cell movement was monitored by live-cell 
imaging. Cell tracking analysis was performed with ImageJ software (National Institutes of 
Health, Bethesda, USA). 
 
Cell Spreading Assay 
The xCELLigence system (Roche Applied Science) was used to analyze the effect of PPARδ 
ligand GW0742 on cell adhesion and spreading according to the manufacturer’s instructions. 
Briefly, HUVECs pretreated with 3 µM GW0742 for 18 hours were seeded onto a 96-well-
microtiter xCELLigence assay plate (E-plate; 10.000 cells per well) and placed on the Real-time 
xCELLigence Cell Analyzer platform to continuously measure impedance changes across 
microelectrodes integrated on the bottom of the E-plates. Impedance changes occur if cell 
attach to E-plates or change their size, shape and numbers.  
 
Chromatin Immunoprecipitation Assay 
Chromatin immunoprecipitation (ChIP) assays were performed using a ChIP assay kit from 
Upstate as previously described.(7) Briefly, cells were treated with 10 µM GW0742 and 
stimulated with TNFα (10 ng/ml) as indicated. Cells were crosslinked with 2 mmol/L 
disuccinimidyl glutarate for 45 minutes before crosslinking for 15 minutes with 1% formaldehyde. 
This 2-step crosslinking method has been shown to be more efficient than the conventional 
single formaldehyde crosslinking procedure.(8) After lysis, cells were sonicated and chromatin 
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fragments were immunoprecipitated with an antibody directed against Bcl-6 overnight at 4˚C. 
Rabbit IgG was used as a negative control. DNA fragments were purified from chromatin using 
the QIAquick PCR Purification Kit (QIAGEN) according to the instructions of the manufacturer. 
The final DNA extractions were amplified by PCR using specific primers for the IL-6, MCP-1 and 
VCAM promoter. An equal volume of nonprecipitated (input) genomic DNA was amplified as 
positive control. The PCR products were resolved on 2% agarose gels and visualized using 
ethidium bromide. 
 
Measurement of Cellular Bioenergetic Function Using the XF-24 Extracellular Flux 
Analyzer 
The XF24 Extracellular Flux Analyzer (Seahorse Bioscience; Billerica) was used to analyze the 
effect of PPARδ ligand GW0742 on both acute and chronic PDGF-treatment induced glycolytic 
flux and mitochondrial respiration in rVSMCs. The oxygen consumption rate (OCR) and the 
extracellular acidification rate (ECAR) were determined following treatment with or without 
GW0742 and/or PDGF stimulation. Cell culture medium was changed prior to the bioenergetic 
measurements to serum-free unbuffered (without sodium bicarbonate) DMEM medium 
supplemented with 2 mM L-glutamine, 5.5 mM D-glucose and 1 mM sodium pyruvate. Basal 
OCRs and ECARs were measured, followed by the sequential injection of 2 µg/ml oligomycin 
and 1 uM FCCP (carbonyl cyanide p-trifluoromethoxy-phenylhydrazone) and 2.5 uM of each 
rotenone/antimycin A. Total cell number, determined after each experiment, was determined by 
DAPI staining and light microscopy and used to normalize glycolytic rates and mitochondrial 
oxidation. 
 
Transient Transfections and Luciferase Assay 
Transient transfections of rVSMCs were performed in triplicate using FuGENE 6 reagent 
(Roche). Luciferase activity was assayed with the Dual-Luciferase Reporter Assay System 
(Promega) according to manufacturer’s instructions. Transfection efficiency was adjusted by 
normalizing firefly luciferase activities to renilla luciferase activities generated by co-transfecting 
pRL-TK (Promega).  
 
Platelet-rich Plasma 
Blood was collected in citrated tubes from apparently healthy subjects who did not take any 
drugs known to interfere with platelet aggregation for at least 14 days. Human platelet-rich 
plasma was prepared by centrifugation of citrate-anticoagulated blood at 120 g for 15 min. 
Mouse platelet-rich plasma was prepared by collecting blood from the vena cava inferior of 12 
week old female PPARδ+/+ and PPARδ-/- mice, followed by centrifugation at 90 g for 12 min.  
 
Stent Perfusion in Vitro 
PPARδ ligand (GW0742-Me) and vehicle (EtOH) coated stents were implanted into a closed-
loop system and perfused with platelet rich plasma. Measurements were taken immediately after 
the filling of the perfusion system and after 1, 11 and 21 circulations. Thrombocyte aggregation 
and activation was determined as described previously.(9) The thrombin-antithrombin III-
complex was measured using the ELISA Enzygnost TAT (Behringwerke, Germany). 
 
Flow cytometry 
Formaldehyde fixed thrombocytes were processed for flow cytometric analysis, which was 
carried out on a Cytomics FC 500, equipped with the CXP software (Beckman Coulter®, Krefeld, 
Germany). A calibration of the device was performed prior to all analyses including the Immuno-
Brite™ standard kit (Beckman Coulter®, Krefeld, Germany) and FluoroSpheres calibration 
beads (Dako, Hamburg,Germany). Mean thrombocyte receptor densities were calculated from 
the mean equivalent fluorochrome amounts using the FluoroSpheres calibration beads (Dako, 
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Hamburg, Germany) as standards. The ratio of the fluorochrome molecules to the number of 
antibody molecules (F/P ratio) was calculated batch-specific, according to the information of the 
supplier. To identify thrombocytes, samples were stained for the GPIb/IX thrombocyte 
membrane glycoprotein (anti-CD42b-PE (Clone SZ2), Immunotech, Beckman Coulter; anti-
CD42a-FITC (Clone Beb1), Becton Dickinson Bioscience). The lysosomal membrane associated 
glycoprotein 3 (anti-CD63-FITC (Clone CLBGran/12), Immunotech, Beckman Coulter) and the 
activated GPIIbIIIa receptor (anti-PAC-1-FITC, Becton Dickinson Bioscience) were analyzed, as 
markers for the activation of thrombocytes. 
 
Platelet Aggregation in Vitro 
Platelet aggregation was carried out according to the turbidimetric method of Born in a four-
channel light transmission aggregometer (APACT-4004; Haemochrom Diagnostica, 
Germany).(10) Platelet-rich plasma was pre-incubated with the PPARδ ligand GW0742 before 
stimulation of aggregation by addition of either adenosine diphosphat (ADP, 10 µM), collagen (5 
µg/ml) or ristocetin (0.75 mg/ml). To measure aggregation on mouse platelets, fibrinogen had to 
be added, which serves as a ligand to cross-link platelets. Thus, mouse platelet-rich plasma was 
diluted in human platelet poor plasma. The PPARδ ligand GW0742 was solved in ethanol. 
Ethanol had no effect on platelet aggregation (data not shown). 
 
Statistical Analysis 
All data are expressed as mean ± standard error of mean (SEM). The data displayed normal 
variance. Intergroup differences were appropriately assessed by either unpaired two-tailed 
Student´s t-test (for comparison of two groups) or one-way analysis of variance (ANOVA) with 
Bonferroni´s post-hoc test (for comparison of more than two groups). The significance threshold 
was set at P≤0.05. Statistical analysis were performed using GraphPad PRISM v6 (GraphPad 
Software®). 
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SUPPLEMENTAL MATERIAL 
 
SUPPLEMENTAL RESULTS 
Release Kinetic of PPARδ Ligand Coated Stents 
For determination of pharmacological release kinetics, PPARδ (GW0742) coated stents (n=3) 
were deployed ex vivo and submersed in 1 ml PBS at 37°C. Samples harvested at distinct time 
points were subjected to high-performance liquid chromatography (HPLC)-based analysis. Time 
dependent HPLC-based analysis of GW0742 elution from coated stents indicated that most of 
the ligand was released within the first 15 min (Supplemental Figure IA, left). Although an 
optimal release kinetic has not been determined so far for any compound used on drug eluting 
stents, a release kinetic within a few hours is not satisfactory. 
To achieve a longer release kinetic we modified the synthetic PPARδ ligand GW0742. GW0742 
has a single carboxyl group within its structure which is suitable for forming ester compounds. 
Diazomethane was utilized to produce methylesters of GW0742 (GW0742-Me) and thus to 
modify the solubility (Supplemental Figure IIA). After methylation, the release of PPARδ ligand 
from the stent in vitro was extended to more than 2 weeks (Supplemental Figure IA, right). The 
surface of a GW0742-Me-coated stent is depicted in Supplemental Figure IB. Importantly, both 
GW0742 and GW0742-Me exert similar biological effects, as determined by quantification of the 
PPARδ target gene Adfp (adipose differentiation related protein) expression in J774 cells in 
response to ligand treatment (Supplemental Figure IIB). In addition, cotransfection of PPARδ 
followed by GW0742 and GW0742-Me stimulation induced PPRE reporter activity in a 
comparable manner (4.67-fold at 10 µM GW0742 and 5.56-fold at 10 µM GW0742-Me versus 
unstimulated cells; P<0.05; Supplemental Figure IIC). 
To determine the pharmacokinetics of PPARδ ligand-coated stents in vivo, rabbits (n=4) were 
stented in the abdominal aorta and euthanized on day three after stenting. Blood samples, 
drawn 15 min after intervention and subsequently at 6, 12, 24 and 48 hours after stenting, 
revealed perceptible PPARδ ligand blood levels with a maximum at 6 h after stent deployment 
(Supplemental Figure IC, left). PPARδ ligand levels in the vascular wall were determined 3 days 
after stent placement. Measurement of the concentrations of both GW0742-Me and GW0742 in 
serum and vessel wall using the Triple-Quadrupole Tandem Mass Spectrometer Agilent 6410 
combined with the Agilent 1200 HPLC System revealed a rapid conversion of GW0742-Me to 
GW0742 (Supplemental Figure IC, right). 
 
PPARδ Induces Transcription of Heme Oxygenase-1 in VSMCs 
Previous studies have shown that heme oxygenase-1 (HO-1), an inducible stress protein known 
for its cytoprotective functions, exerts antiproliferative effects in VSMCs.(11, 12) To determine 
the effect of synthetic PPARδ ligands on HO-1 expression, quiescent rVSMCs were incubated 
with GW0742 as indicated. As shown in Figure IVA, PPARδ agonist treatment markedly 
increased HO-1 mRNA (2.23-fold induction versus unstimulated cells; P<0.05) and protein 
expression. To address the role of PPARδ in regulating HO-1 expression, serum-deprived 
PPARδ+/+ and PPARδ-/- mVSMCs were used. Stimulation of PPARδ wildtype mVSMCs with 
GW0742 induced HO-1 mRNA expression (2.85-fold induction versus unstimulated cells; 
P<0.05), whereas no effect was observed in PPARδ knockout cells (Figure IVB). Taken together, 
these results indicate that PPARδ ligands induce HO-1 gene transcription in a receptor-
dependent manner. To identify the HO-1 promoter elements that mediate the response to 
ligand-activated PPARδ, we used a series of 5’-deletion constructs. As depicted in Figure IVC, 
the inducibility by GW0742 was lost in the -66HO1-Luc and -35HO1-Luc constructs.  
As previous studies reported a growth-inhibitory effect of HO-1,(11, 12) we therefore conclude 
that the enhanced HO-1 expression in response to PPARδ ligand treatment contributes to its 
anti-proliferative effect. 
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Supplemental Figure Legends 
Suppl. Figure I 
(A) Pharmacokinetics of GW0742 and GW0742-Me coated stents in vitro (n = 3 per group). 
Cumulative GW0742 (left) and GW0742-Me (right) release profile in PBS solution at 37˚C. (B) 
GW0742-Me-coated surface of an unexpanded stent (scale bar: 100 µM). (C) Kinetics of drug 
release from GW0742-Me coated stents under in vivo conditions (n = 4 per group). Release into 
the blood stream was characterized by measuring the serum levels of both GW0742-Me and the 
deconjugated GW0742 since the methylester is rapidly cleaved, presumably by esterases 
present in the plasma (left). Right panel shows the tissue levels of GW0742 (GW) and GW0742-
Me (GW-Me) in the vascular wall 3 days after stent implantation.  
 
Suppl. Figure II 
(A) The chemical structure of PPARδ ligand GW0742 (GW) and methylester conjugated PPARδ 
ligand GW0742-Me (GW-Me). (B) Serum-deprived J774A.1 cells were treated with 10 µM 
GW0742 or GW0742-Me for 24 hours. Cells were the harvested and analyzed for Adfp mRNA 
expression by quantitative real-time PCR. (C) rVSMCs were transiently transfected with a 
PPARδ overexpression plasmid and a PPRE-Luc reporter driven by three PPRE binding sites. At 
24 hours after transfection, cells were stimulated with 10 µM GW0742 or GW0742-Me. Firefly 
luciferase activity was analyzed and normalized to renilla luciferase activity obtained by co-
transfecting pRL-TK. Data are presented as fold induction±SEM over unstimulated control. 
*P<0.05 vs unstimulated cells, one-way ANOVA with post hoc correction (Bonferroni). 
 
Suppl. Figure III 
(A) Study layout of stent placement in a rabbit model of experimental atherosclerosis. (B) 
Representative photographs of rabbit aortas after denudation and additional 4 weeks of 
atherogenic diet illustrating the development of atherosclerotic lesions. Serial sections were 
stained with trichrom-elastin, for macrophages (Mac-2) and for endothelial cells (CD31). (C) 
Representative angiograms before stent deployment, during balloon inflation and after stent 
placement. 
 
Suppl. Figure IV 
PPARδ activation induces heme oxygenase-1 (HO-1) mRNA and protein expression in G1-
arrested rVSMCs (A) and PPARδ+/+ mVSMCs (B). Rat VSMCs and PPARδ+/+ (PPARδ WT) and 
PPARδ-/- (PPARδ KO) mVSMCs were serum-starved for 24 hours followed by stimulation with 
GW0742 (GW) as indicated. HO-1 mRNA and protein expression was analyzed by quantitative 
real-time PCR (normalized to GAPDH mRNA expression) or Western blotting, normalized to 
smooth muscle actin (SMA). (C) Regulation of the HO-1 promoter by PPARδ. Rat VSMCs were 
transiently transfected with HO-1 promoter constructs, followed by stimulation with GW0742 (10 
µM). Luciferase activity was assayed 24 hours after PPARδ ligand treatment. Data are 
expressed as fold induction±SEM over unstimulated control (Con). *P<0.05 vs. unstimulated 
cells, one-way ANOVA with post hoc correction (Bonferroni). Western blots are representative of 
3 independent experiments. 
 
Suppl. Figure V 
Re-endothelialization of vehicle (ethanol) and PPARδ ligand (GW0742-Me) coated stents 14 
days after deployment in rabbit atheromatous arteries (n = 8 per group). (A) Representative 
arterial sections stained with an antibody against PECAM-1 (platelet endothelial cell adhesion 
molecule-1) to visualize endothelial cells. (B) Quantification of luminal endothelial cell coverage. 
Results are presented as mean±SEM, Student´s t-test. 
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Suppl. Figure VI 
Proposed mechanism of PPARδ ligand coated stents in suppressing neointima formation and 
stent thrombosis. 
 
Suppl. Table I 
Metabolic parameters (A) and differential blood count (B) of rabbits 42 days after deployment of 
vehicle (EtOH) and GW0742-Me coated stents. Values are expressed as mean±SEM, one-way 
ANOVA with post hoc correction (Bonferroni). 
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Figure 6
